Metzger Michael A 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Syndax (SNDX) CEO Michael A. Metzger Sells 17,159 Shares
What Happened
- Michael A. Metzger, CEO of Syndax Pharmaceuticals (SNDX), sold 17,159 shares on Feb 9, 2026 at $21.03 per share, yielding approximately $360,819. The Form 4 reports the transaction as a sale (S) and indicates the shares were disposed to satisfy tax withholding tied to vested restricted stock units.
Key Details
- Transaction date and price: Feb 9, 2026 — 17,159 shares at $21.03 each (total ≈ $360,819).
- Transaction type: Sale (reported as open market or private sale); filing does not specify which.
- Footnote: Sale executed to cover tax withholding obligations from RSU vesting (per filing).
- Shares owned after transaction: Not specified in this Form 4.
- Filing timeliness: Form filed Feb 10, 2026 (next day) — appears to be timely.
Context
- Sales to cover tax withholding on vesting RSUs are routine and are not the same signal as a discretionary, portfolio-rebalancing sale; they often reflect mandatory withholding rather than a view on the stock.
- No options were exercised and no 10b5-1 plan or gift was reported in this filing.
Insider Transaction Report
Form 4
Metzger Michael A
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1]2026-02-09$21.03/sh−17,159$360,819→ 491,690 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
Signature
/s/ Michael A. Metzger|2026-02-10